---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-014881"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2022-05-19T23:59:59+00:00"
generated_at: "2026-06-25T09:08:04.222672+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ChromaDex forms JV to commercialize Tru Niagen in China; gets 71% voting interest

## Summary
- JV partners Crystal Lake, Pioneer Idea, Taikuk contribute $1.8M, $1.2M, $1.0M total $4M into the JV.
- ChromaDex holds 71% voting interest, appoints 3 of 5 directors; Taikuk gets 11% non-voting interest after $1M fee.
- JV to commercialize Tru Niagen and other NR products in Mainland China (excl. HK, Macau, Taiwan) under 20-year term.
- Health food (Blue Hat) registration with China SAMR required for broad distribution; must be obtained within 24 months of closing.
- JV expects to enter distribution agreement with Sinopharm Xingsha upon regulatory approval; closing targeted by Q3 2022.

## SEC filing metadata
- accession: 0001628280-22-014881
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2022-05-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828022014881/0001628280-22-014881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828022014881/cdxc-20220519.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-014881
- JSON: https://secwatch.observer/filing/0001628280-22-014881.json
- Plain text: https://secwatch.observer/filing/0001628280-22-014881.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.